Cited by 168Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersChromatin Remodeling and Cancer

Molecular genetics of adrenocortical tumours, from familial to sporadic diseases

Libé, Rossella, Bertherat, Jérôme·2005·European Journal of Endocrinology

Abstract

Adrenal masses can be detected in up to 4% of the population, and are mostly of adrenocortical origin. Adrenocortical tumours (ACTs) may be responsible for excess steroid production and, in the case of adrenocortical cancers, for morbidity or mortality due to tumour growth. Our understanding of the pathogenesis of ACTs is more limited than that for other tumours. However, studies of the genetics of ACTs have led to major advances in this field in the last decade. The identification of germline molecular defects in the hereditary syndrome responsible for ACTs has facilitated progress. Indeed, similar molecular defects have since been identified as somatic alterations in sporadic tumours. The familial diseases concerned are Li-Fraumeni syndrome, which may be due to germline mutation of the tumour-suppressor gene TP53 and Beckwith-Wiedemann syndrome, which is caused by dys-regulation of the imprinted IGF-II locus at 11p15. ACTs also occur in type 1 multiple endocrine neoplasia (MEN 1), which is characterized by a germline mutation of the menin gene. Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD) has been observed in Carney complex patients presenting inactivating germline PRKAR1A mutations. Interestingly, allelic losses at 17p13 and 11p15 have been demonstrated in sporadic adrenocortical cancer and somatic PRKAR1A mutations have been found in secreting adrenocortical adenomas. More rarely, mutations in Gs protein (gsp) and the gene for ACTH receptor have been observed in ACTs. The genetics of another group of adrenal diseases that can lead to adrenal nodular hyperplasia -- congenital adrenal hyperplasia (CAH) and glucocorticoid-remediable aldosteronism (GRA) -- have also been studied extensively. This review summarizes recent advances in the genetics of ACTs, highlighting both improvements in our understanding of the pathophysiology and the diagnosis of these tumours.

Integrity signals

Registry

Crossref · 10.1530/eje.1.02004

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Perturbation of the IGF2 locus, with upregulation of IGF2 and downregulation of H19 and CDKN1C, is frequently observed in ACCs.

    “Perturbation of the IGF2 locus, with upregulation of maternally imprinted genes (IGF2), and downregulation of paternally imprinted genes (H19 and CDKN1C), is frequently observed in ACCs (226).”

    From Adrenocortical carcinoma (2014) · cites this paper as [226]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Libé, R., & Bertherat, J.
Venue
European Journal of Endocrinology
Published
2005-10
Volume
153
Issue
4
Pages
477-487
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2171162119
Cited by
168
References
106
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 8 · 2015: 11 · 2014: 14 · 2013: 6 · 2012: 13
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
adrenocortical tumors, adrenocortical carcinoma, adrenal adenoma, Li-Fraumeni syndrome, TP53, Beckwith-Wiedemann syndrome, multiple endocrine neoplasia type 1, Carney complex, PRKAR1A mutation, Cushing's syndrome, primary pigmented nodular adrenocortical disease, loss of heterozygosity, 17p13, 11p15, ACTH receptor, adrenal nodular hyperplasia, congenital adrenal hyperplasia, glucocorticoid-remediable aldosteronism, hereditary cancer, somatic mutations
MeSH terms
Adrenal Cortex Neoplasms, Humans, Molecular Biology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review